Refine by
Cognitive Impairment Articles & Analysis
38 news found
Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases CY6463 favorable tolerability and safety profile was confirmed Ariana Pharma, a leading Artificial Intelligence (AI) drug development company, in collaboration with Cyclerion Therapeutics, presented today safety and ...
The GRADUATE Phase 3 program evaluated the safety and efficacy of gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer’s and mild Alzheimer’s dementia over 27 months. 1,965 study participants across 30 countries were randomized 1:1 to receive gantenerumab or placebo by subcutaneous injection titrated to reach a target dose of ...
DN-TNF is in clinical trials to determine if it can treat cancer (INB03™), Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. ...
Healthbit’s dementia app is the world’s first clinically evidenced app for patients with mild dementia or mild cognitive impairment (MCI) and their carers.Evidenced through a ground-breaking randomised control trial (RCT), the app has been shown to benefit people living with dementia and their carers in a number of ways. ...
“We plan to invest most of our proceeds into our final phase III clinical trials for intranasal insulin for mild cognitive impairment in Alzheimer’s. Kurve Therapeutics is ready for Phase III clinical trials in three separate disease states and is one Phase III study away from being eligible for FDA ...
“Identifying Alzheimer’s disease as the underlying cause of memory loss and cognitive impairment will allow physicians to develop a better patients care map by providing patients with better quality of life plans and treatment options,” said Dr. ...
Medical Director Jay Pathmanathan, MD, PhD, discussed how the company has applied its machine learning platform to standard electroencephalography (EEG) data to detect electrical disturbances in the brain that may predict cognitive decline and explain variability in disease course for patients with Alzheimer's disease. ...
The Women’s Brain Project, an international non-profit organization studying gender and sex determinants to brain and mental health and Altoida, a precision neurology company pioneering non-invasive brain health diagnostics using AI and augmented reality (AR), today announced results from a study showing sex-based differences using digital biomarker data collected from Altoida’s ...
The Women’s Brain Project, an international non-profit organization studying gender and sex determinants to brain and mental health and Altoida, a precision neurology company pioneering non-invasive brain health diagnostics using AI and augmented reality (AR), today announced results from a study showing sex-based differences using digital biomarker data collected from Altoida’s ...
Altoida’s technology platform uses artificial intelligence (AI) to analyze cognitive and functional test results and help diagnose neurological diseases, like Mild Cognitive Impairment (MCI) and Alzheimer’s. ...
The collaboration will analyze data from completed Phase 1 clinical studies of CY6463, including a completed translational pharmacology study in healthy elderly subjects, as well as an ongoing study in Cognitive Impairment Associated with Schizophrenia (CIAS). Insights from these analyses are expected to accelerate and support further clinical development of ...
About Fragile X Syndrome Fragile X syndrome affects roughly 1 in 4,000 males and 1 in 8,000 females and causes a range of developmental problems including behavioral problems and cognitive impairment. Currently, there are no effective treatments or cures for the condition, but Healx is launching an adaptive clinical study to evaluate the efficacy of several ...
Altoida, Inc. an AI company pioneering next-generation neurological disease diagnostics, and GN Group, a global leader in intelligent audio solutions, have signed a multi-year strategic partnership to research and develop new digital biomarkers for identifying Mild Cognitive Impairment (MCI). The research will serve as the backbone for new augmented reality tools ...
In 2021, Altoida won FDA Breakthrough Device Designation for development of their device to use artificial intelligence to predict the likelihood that an individual aged 55+ with Mild Cognitive Impairment will convert to Alzheimer’s disease. The company also launched groundbreaking research studies with Eisai and Ionian University in Alzheimer’s ...
The PrecivityAD™ test is a breakthrough blood test intended for use in patients with cognitive impairment. The test helps physicians determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease (AD). ...
Manus Neurodynamica Limited (“Manus”), who develop and market products and technologies for neuromotor assessment, will be joining the ABHI UK Pavilion at MEDICA 2021 (15 – 18 November 2021) to launch their revolutionary non-invasive technology that supports an earlier and more accurate diagnosis of dementias and cognitive impairment. The ...
This funding could allow us to make a significant difference by changing mindsets when it comes to Brain Health and hopefully ease millions of worried patients around the world by detecting the causes of their cognitive impairment and providing them access to novel therapeutics,” said David Lapointe, CEO Optina Diagnostics. ...
C2N’s PrecivityAD™ test is a breakthrough blood test intended for use in patients with cognitive impairment. The test helps physicians determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease. ...
” She and her colleagues studied 895 participants with early disease and patients with mild cognitive impairment from two independent cohorts. Separately, a group of leading researchers[1] presented their round-robin findings that measuring amyloid beta (Aβ) in a patient’s blood can be a pre-screen or a substitute for costly PET scans or ...
C2N Diagnostics, which offers the first widely accessible blood test to help physicians with Alzheimer’s disease diagnosis, announces that Rhode Island physicians can now use PrecivityAD™ to aid in the evaluation of their patients showing cognitive impairment. Rhode Island has joined 46 other states, the District of Columbia and Puerto Rico in ...